HC Wainwright lowered Pharming Group’s third-quarter 2026 EPS estimate to $0.20. The previous estimate for the period was $0.30. This revision follows Pharming’s July 30 second-quarter financial results, which missed analyst expectations.
Pharming reported Q2 revenue of $90.2 million. The company posted a Q2 EPS of $0.02. Both figures fell short of consensus estimates.
Pharming reduced its full-year 2026 revenue guidance by approximately $30 million. The new guidance range is $375 million to $395 million.
Management attributed the reduction to weaker sales of its legacy product, RUCONEST. The negative guidance drove recent declines in the company's stock price.